Xenon Pharmaceuticals Inc. (XENE)
USD 39.35
(-4.68%)
USD 39.35
(-4.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | 9.43 Million | 18.43 Million | 32.16 Million | 6.82 Million | - |
| Cost of Revenue | 167.51 Million | 105.76 Million | 75.46 Million | 50.52 Million | 38.84 Million | 6 Million |
| Gross Profit | -167.51 Million | -96.33 Million | -57.02 Million | -18.35 Million | -32.01 Million | -6 Million |
| Operating Expenses | 46.54 Million | 138.57 Million | 97.43 Million | 63.46 Million | 49.64 Million | 32.01 Million |
| Selling, General and Administrative Expenses | 46.54 Million | 32.81 Million | 21.96 Million | 12.94 Million | 10.8 Million | 8.38 Million |
| Research and Development Expenses | 167.51 Million | 105.76 Million | 75.46 Million | 50.52 Million | 38.84 Million | 23.63 Million |
| Other Expenses | -167.51 Million | 3.88 Million | 105 Thousand | 2.2 Million | - | 4.39 Million |
| Cost and Expenses | 214.05 Million | 138.57 Million | 97.43 Million | 63.46 Million | 49.64 Million | 38.01 Million |
| Operating Income | -214.05 Million | -129.14 Million | -78.99 Million | -31.3 Million | -42.81 Million | -38.01 Million |
| Interest Expense | - | - | - | 484 Thousand | 1.43 Million | 1.39 Million |
| Income Tax Expense | 292 Thousand | 118 Thousand | -6000.00 | -257 Thousand | -23 Thousand | 4.91 Million |
| Earnings before Tax | -182.68 Million | -125.25 Million | -78.88 Million | -29.09 Million | -41.61 Million | -34.49 Million |
| Net Income | -182.39 Million | -125.37 Million | -78.88 Million | -28.83 Million | -41.59 Million | -34.49 Million |
| Earnings Per Share Basic | -2.73 | -2.07 | -1.81 | -0.83 | -1.60 | -1.78 |
| Earnings Per Share Diluted | -2.73 | -2.07 | -1.81 | -0.83 | -1.60 | -1.78 |
| Weighted Average Shares Outstanding | 66.88 Million | 60.54 Million | 43.62 Million | 34.54 Million | 25.93 Million | 19.42 Million |
| Weighted Average Shares Outstanding (Diluted) | 66.88 Million | 60.54 Million | 43.62 Million | 34.54 Million | 25.93 Million | 19.42 Million |
| Gross Margin | - | -10.21 | -3.09 | -0.57 | -4.69 | - |
| EBIT Margin | - | -13.69 | -4.28 | -0.97 | -5.86 | - |
| Profit Margin | - | -13.29 | -4.28 | -0.90 | -6.09 | - |
| EBITDA | -210.51 Million | -127.51 Million | -78.08 Million | -27.96 Million | -39.75 Million | -32.54 Million |
| Earnings Before Tax Margin | - | -13.69 | -4.28 | -0.97 | -6.27 | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 5.38 Million | - | - |
| Cost of Revenue | 659 Thousand | 599 Thousand | 3.54 Million | 851 Thousand | 1.73 Million | 602 Thousand |
| Gross Profit | -659 Thousand | -599 Thousand | -3.54 Million | 4.52 Million | -1.73 Million | -602 Thousand |
| Operating Expenses | 68.44 Million | 58.44 Million | 210.51 Million | 52.84 Million | 55.68 Million | 55.62 Million |
| Selling, General and Administrative Expenses | 18.74 Million | 14.19 Million | - | 11.76 Million | 12.8 Million | 11.58 Million |
| Research and Development Expenses | 49.7 Million | 44.25 Million | - | 41.07 Million | 42.88 Million | 44.04 Million |
| Other Expenses | -49.7 Million | - | - | -15 Million | 7.06 Million | 7.94 Million |
| Cost and Expenses | 69.1 Million | 59.04 Million | 214.05 Million | 53.69 Million | 55.68 Million | 55.62 Million |
| Operating Income | -69.1 Million | -59.04 Million | -214.05 Million | -53.69 Million | -55.68 Million | -55.62 Million |
| Interest Expense | - | - | - | 7.61 Million | - | - |
| Income Tax Expense | -333 Thousand | 412 Thousand | -292 Thousand | -205 Thousand | -157 Thousand | -220 Thousand |
| Earnings before Tax | -58.25 Million | -47.51 Million | -182.68 Million | -44.94 Million | -48.61 Million | -47.68 Million |
| Net Income | -57.92 Million | -47.93 Million | -182.39 Million | -44.74 Million | -48.46 Million | -47.46 Million |
| Earnings Per Share Basic | -0.75 | -0.62 | - | -0.64 | -0.73 | -0.72 |
| Earnings Per Share Diluted | -0.75 | -0.62 | - | -0.64 | -0.73 | -0.72 |
| Weighted Average Shares Outstanding | 77.67 Million | 77.59 Million | 66.88 Million | 69.96 Million | 66 Million | 65.86 Million |
| Weighted Average Shares Outstanding (Diluted) | 77.67 Million | 77.59 Million | 66.88 Million | 69.96 Million | 66 Million | 65.86 Million |
| Gross Margin | - | - | - | 0.84 | - | - |
| EBIT Margin | - | - | - | -9.82 | - | - |
| Profit Margin | - | - | - | -8.32 | - | - |
| EBITDA | -68.44 Million | -58.44 Million | - | -52.84 Million | -55.68 Million | -55.62 Million |
| Earnings Before Tax Margin | - | - | - | -9.98 | - | - |
ADVANC
BH-R
ADVANC-R
300936
BIZOTIC
MPIX